HomeNDC LookupIngredientsTobramycin › 24208-0290-05
Tobramycin 3 mg/mL Solution — NDC 24208-0290-05 package photo

Tobramycin 3 mg/mL Solution

by Bausch & Lomb Incorporated · 1 BOTTLE, DROPPER in 1 CARTON (24208-290-05) / 5 mL in 1 BOTTLE, DROPPER
NDC 24208-0290-05
🏷️ FDA NDC (as labeled) 24208-290-05 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 24208-290-05
Product NDC 24208-290
11-digit billing NDC 24208029005
NCPDP billing unit ML — per mL (volume)
RxCUI 313415
UNII VZ8RRZ51VK
UPC 0324208290057
Application # ANDA064052
SPL Set ID a5693ec9-d2f7-4d45-90b0-a113c54840d7
Established class (EPC) Aminoglycoside Antibacterial
Chemical class Aminoglycosides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1993-11-29
Route OPHTHALMIC
Dosage form SOLUTION
Substance TOBRAMYCIN
GPI-14 86101070002005
GPI class Tobramycin
GCN Seq No 038588
GCN 09384
HICL code 017765
Ingredient (HICL) Tobramycin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 08:12.02.00
AHFS class Aminoglycoside Antibiotics
FDB label name TOBRAMYCIN 0.3% EYE DROP
FDB brand name Tobramycin
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AT · RLD · RS
Why two NDCs? The FDA registers this code as 24208-290-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 24208-0290-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Aminoglycoside Antibacterial class.

Pharmacologic class Aminoglycoside Antibacterial
Drug family (ATC) Other aminoglycosides, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerBausch & Lomb Incorporated
Application holderBAUSCH AND LOMB INC
FDA applicationANDA064052 (ANDA)
Labeler code24208
First marketedNov 1993
Product typeHuman Prescription Drug
Portfolio92 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name TOBRAMYCIN 0.3% EYE DROP Ingredient Tobramycin
📖 What it is MedlinePlus · NLM

Ophthalmic tobramycin is used to treat eye infections. Tobramycin is in a class of medications called antibiotics. It works by killing bacteria that cause infections.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • That on-off cycle is how the inhaled tobramycin products are designed to work for cystic fibrosis. You use it for 28 days to reduce the Pseudomonas aeruginosa bacteria in your lung...
  • I have cystic fibrosis. Why is tobramycin given in a cycle of 28 days on and 28 days off?
  • No — TOBI Podhaler capsules must never be swallowed. They are specially designed to be inhaled using the Podhaler device, which delivers the medicine directly to your lungs where i...
  • Can I swallow the TOBI Podhaler capsules if I have trouble using the inhaler?
📖 Read our full Tobramycin guide →
8
Nutrient depletion considerations

Tobramycin may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII R57ZHV85D4
    Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 0YPR65R21J
    Sodium sulfate is a mineral salt used in pharmaceuticals as a filler and diluent. It helps provide bulk and stability to tablets and capsules while remaining inert in the body.
  • UNII O40UQP6WCF
    A strong acid used in small amounts to adjust and maintain the pH balance of a medicine, helping ensure stability and proper dissolution of the active ingredients.
  • UNII Y27PUL9H56
    Tyloxapol is a synthetic detergent and surfactant used in medications as a solubilizer and emulsifier. It helps dissolve or blend ingredients that don't naturally mix well, improving how the medicine disperses in liquid formulations.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $1.158 $5.79 / 5 ml
Medicaid paysCMS SDUD · 12 mo $2.42 $12.08 / 5 ml
Medicare drug plans payPart D · Q2 2026 $0.9370 $4.69 / 5 ml
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $1.805 $1.002
▼ Down 21% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Tobramycin 3 mg/mLthis 24208-0290-05 Bausch 1 bottle $1.158 AT Availability likely
Tobramycin 3 mg/mL 61314-0643-05 Sandoz 5 ml $1.158 AT Availability likely
Tobramycin Ophthalmic Solution 3 mg/mL 62332-0518-05 Alembic 1 bottle $1.158 AT Availability likely
Tobramycin 3 mg/mL 70069-0131-01 Somerset 1 bottle $1.158 AT Availability likely
Tobramycin Ophthalmic Solution 3 mg/mL 46708-0518-05 Alembic 1 bottle AT FDA listed
Tobramycin 3 mg/mL 50090-2127-00 A-S 1 bottle AT FDA listed
Tobramycin 3 mg/mL 50090-4190-00 A-S 1 bottle AT FDA listed
Tobramycin 3 mg/mL 60760-0583-05 St. 1 bottle AT FDA listed
Tobramycin 3 mg/mL 61919-0642-05 DirectRX 5 ml AT FDA listed
Tobramycin 3 mg/mL 62250-0110-01 Belcher 1 bottle AT FDA listed
Tobramycin 3 mg/mL 63187-0024-05 Proficient 1 bottle AT FDA listed
Tobramycin 3 mg/mL 63187-0902-02 Proficient 1 bottle FDA listed
Tobramycin 3 mg/mL 63187-0973-05 Proficient 5 ml AT FDA listed
Tobramycin 3 mg/mL 66267-0936-05 NuCare 5 ml AT FDA listed
Tobramycin 3 mg/mL 68071-2272-05 NuCare 1 bottle AT FDA listed
Tobramycin 3 mg/mL 68083-0374-01 Gland 1 bottle AT FDA listed
Tobramycin 3 mg/mL 68788-7252-05 Preferred 1 bottle AT FDA listed
Tobramycin 3 mg/mL 70518-1370-00 REMEDYREPACK 1 bottle AT FDA listed
Tobramycin 3 mg/mL 71205-0101-05 Proficient 1 bottle AT FDA listed
Tobramycin 3 mg/mL 76420-0092-05 Asclemed 5 ml AT FDA listed
Tobramycin 3 mg/mL 76420-0791-05 Asclemed 1 bottle AT FDA listed
Tobramycin 3 mg/mL 80425-0341-01 Advanced 1 bottle AT FDA listed
Tobramycin 3 mg/mL 85766-0025-05 Sportpharm 1 bottle AT FDA listed
Tobramycin 3 mg/mL 85766-0189-05 Sportpharm 1 bottle AT FDA listed
Tobramycin 3 mg/mL 86211-0110-01 JVET 1 bottle AT FDA listed
Tobramycin 3 mg/mL 68788-4149-05 Preferred 1 bottle AT FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1993
On the market since
Nov 1993
📍
2026
Currently FDA-listed
33 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 24208-0290-05, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
18.1K
Units reimbursed last 4 qtrs
93.6K
Gross reimbursed last 4 qtrs
$226K
Avg / prescription
$12.50
Avg / unit
$2.4155
Latest quarter Q4 2025
8KRx
Medicaid pays / mL
$2.4155
gross reimbursed
vs
NADAC / mL
$1.1579
acquisition cost
=
Spread
+$1.2576
+109% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
31% FFS 69% MCO
Fee-for-service · 5,618 Rx Managed care · 12,466 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 830 units · 10.6 per 100k residents WA Idaho: 515 units · 26.2 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 1,681 units · 29.3 per 100k residents MN Wisconsin: 1,200 units · 20.3 per 100k residents WI Michigan: 13,470 units · 134 per 100k residents MI New York: 11,110 units · 56.8 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 370 units · 8.7 per 100k residents OR Nevada: 455 units · 14.2 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 1,270 units · 39.6 per 100k residents IA Illinois: 5,655 units · 45.1 per 100k residents IL Indiana: 2,170 units · 31.6 per 100k residents IN Ohio: 4,318 units · 36.6 per 100k residents OH Pennsylvania: 2,003 units · 15.5 per 100k residents PA New Jersey: 4,035 units · 43.4 per 100k residents NJ Massachusetts: 75 units · 1.1 per 100k residents MA California: 5,986 units · 15.4 per 100k residents CA Utah: 185 units · 5.4 per 100k residents UT Colorado: 645 units · 11.0 per 100k residents CO Nebraska: 2,530 units · 128 per 100k residents NE Missouri: 1,332 units · 21.5 per 100k residents MO Kentucky: 2,575 units · 56.9 per 100k residents KY West Virginia: 720 units · 40.7 per 100k residents WV Virginia: 775 units · 8.9 per 100k residents VA Maryland: 1,344 units · 21.7 per 100k residents MD Connecticut: 575 units · 15.9 per 100k residents CT Rhode Island: 55 units · 5.0 per 100k residents RI Arizona: 915 units · 12.3 per 100k residents AZ New Mexico: 3,160 units · 149 per 100k residents NM Kansas: 405 units · 13.8 per 100k residents KS Arkansas: 725 units · 23.6 per 100k residents AR Tennessee: 2,530 units · 35.5 per 100k residents TN North Carolina: 3,140 units · 29.0 per 100k residents NC South Carolina: no data reported SC Delaware: 140 units · 13.6 per 100k residents DE Oklahoma: 1,746 units · 43.1 per 100k residents OK Louisiana: 6,390 units · 140 per 100k residents LA Mississippi: 1,145 units · 38.9 per 100k residents MS Alabama: 415 units · 8.1 per 100k residents AL Georgia: 2,008 units · 18.2 per 100k residents GA D.C.: no data reported DC Hawaii: 105 units · 7.3 per 100k residents HI Texas: no data reported TX Florida: 2,255 units · 10.0 per 100k residents FL
Units reimbursed · per 100k residents
1.1149
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Mexico 149 /100k
2 Louisiana 140 /100k
3 Michigan 134 /100k
4 Nebraska 128 /100k
5 Kentucky 56.9 /100k
6 New York 56.8 /100k
7 Illinois 45.1 /100k
8 New Jersey 43.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Tobramycin — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Tobramycin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$564.7K
Claims incl. refills
354
Beneficiaries
253
Spend / beneficiary
$2,232.06
Spend / claim
$1,595.23
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
24208-0290-05 You're viewing this 1 BOTTLE, DROPPER in 1 CARTON (24208-290-05) / 5 mL in 1 BOTTLE, DROPPER 1993-11-29 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 59 words

INDICATIONS AND USAGE Tobramycin ophthalmic solution, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. Clinical studies have shown tobramycin to be safe and effective for use in children.

⏱️ Dosage and Administration 49 words

DOSAGE AND ADMINISTRATION In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation. FOR TOPICAL OPHTHALMIC USE ONLY do not use

Contraindications 17 words

CONTRAINDICATIONS Tobramycin ophthalmic solution, 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

⚠️ Warnings 59 words

WARNINGS FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution, 0.3% occurs, discontinue use.

🤒 Adverse Reactions 127 words

ADVERSE REACTIONS The most frequent adverse reactions to tobramycin ophthalmic solution, 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution. Postmarketing Experience Additional adverse reactions identified from postmarketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 66 words

Pregnancy Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

🧒 Pediatric Use 18 words

Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

🧓 Geriatric Use 17 words

Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

🧬 Clinical Pharmacology 95 words

CLINICAL PHARMACOLOGY In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci , including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci , including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

📦 How Supplied / Storage and Handling 104 words

HOW SUPPLIED Tobramycin ophthalmic solution USP, 0.3% is supplied in a plastic bottle with a controlled drop tip and a white polypropylene cap in the following size: NDC 24208-290-05 - 5 mL fill in a 10 mL bottle Storage Store at 2°C to 25°C (36°F to 77°F). Avoid excessive heat. After opening, tobramycin ophthalmic solution USP, 0.3% can be used until the expiration date on the bottle.

Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2023 Bausch & Lomb Incorporated or its affiliates Revised: November 2023 9116808 (folded) 9116908 (flat)

📋 Description 94 words

DESCRIPTION Tobramycin ophthalmic solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections. Each mL contains: Active: tobramycin 3 mg (0.3%). Inactives: boric acid, sodium sulfate, sodium chloride, tyloxapol and purified water.

Sodium hydroxide and/or sulfuric acid (to adjust pH). Tobramycin ophthalmic solution, 0.3% has a pH range between 7.0 and 8.0. Preservative: benzalkonium chloride 0.1 mg (0.01%).

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens. The chemical structure of tobramycin is: Chemical name: (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol chem

💬 Information for Patients 17 words

Information for Patients Do not touch dropper tip to any surface, as this may contaminate the solution.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.